Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ny developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... -- BerGenBio AS ("BerGenBio" or the "Company"), ... on the latest data on BGB324, the Company,s first-in-class, ... kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in ... with the 2015 American Society of Clinical Oncology (ASCO) ... 29 - June 2, 2015. The abstract ...
(Date:5/29/2015)... , May 29, 2015 ... p ersonalized   treatments enter arena, says   ... Despite generic erosion facing several of the leading ... (budesonide/formoterol fumarate) and Xolair (omalizumab), the global market for ... the end of the decade.   New ...
(Date:5/29/2015)... Pa. (PRWEB) May 29, 2015 ... Product Solutions with a request to design an ... excess moisture from prescription medications being produced using ... solution that includes a robotic gantry, heat-saving windows, ... and dries trays of 3D-printed pills to exact ...
(Date:5/29/2015)... , May 28, 2015 Research ... addition of Jain PharmaBiotech,s new report "Cytogenetics ... offering. This report deals with cytogenetics ... use mainly to describe the chromosome structure and ... of molecular biology, it is also referred to ...
Breaking Biology Technology:BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3
... , ... ... ... ...
... ... gives corn and soybean growers the opportunity to produce higher yields and stronger crops ... less pressure and improved yield potential. , ... Philadelphia, PA (PRWEB) March 9, 2010 -- As planting season ...
... ... for Best Industry-Exclusive Agency and Best Business Development Program for sanofi-aventis , ... Salem, MA ... pharmaceuticals focused strategic communications agency, announced today that it has won two 2009 ...
Cached Biology Technology:Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 2Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 3Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 4Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 5Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 6Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 7Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 8Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 9Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 10Preemergence Herbicides from FMC Boost Early Season Plant Health in Corn and Soybeans and Help Optimize Yields for 2010 2Preemergence Herbicides from FMC Boost Early Season Plant Health in Corn and Soybeans and Help Optimize Yields for 2010 3LaVoie Group Honored by LACP with Two Awards 2LaVoie Group Honored by LACP with Two Awards 3LaVoie Group Honored by LACP with Two Awards 4
(Date:5/26/2015)... 26, 2015 Research and ... of the "Saudi Arabia Biometric Systems Market ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems ... is projected to grow at over 22% CAGR ... attributed to the surging demand for better biometric ...
(Date:5/21/2015)... DALLAS , May 21, 2015 ... report, "Thermal Imaging Market by Solutions (Hardware, Software, Services), ... Veterinary, Automotive & others), by End-Users (Military & ... published by MarketsandMarkets, Thermal Imaging Market is expected ... $9998.9 Million by 2020, at a Compound Annual ...
(Date:5/19/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... Vitamin and mineral supplements can enhance mental energy and ... prone to anxiety and depression, according to a July ... Technologists (IFT) Annual Meeting & Food Expo held at ... faculty of medicine at the University of Calgary, Alberta, ...
... size and parental behavior are the key drivers in children,s ... the 2013 Institute of Food Technologists (IFT) Annual Meeting & ... crowd of more than 200 conference attendees heard new insights ... eating behaviors are and how the industry and parents can ...
... (OGL), New England Biolabs, Inc., and Northeastern University have reached ... tissue from the world,s most rare, strange, and remarkable ocean ... Ocean Genome Legacy , Founded in 2001 ... New England Biolabs, OGL is a non-profit environmental research organization ...
Cached Biology News:Taste rules for kids and healthy food choices 2Collection that may hold key to ocean's mysteries looks to expand in new waterfront home 2
...
... Top cover cold rolled steel ... Work surface polyethylene ... tempered glass 3 UV lamps ... UV lamp interlocked with fluorescent light ...
... work area that will help protect your ... irradiate the work area prior to use, ... be amplified. Containment features reduce the chance ... acrylic windows for a clear view, an ...
...
Biology Products: